Brief: Enveric Biosciences says Expands Ip Portfolio With U.S. Patent For Novel Carboxylated Psilocybin Derivatives Supporting Evm301 Series Of Drug Candidates
20/09/2023 13:36
Sept 20 (Reuters) - Enveric Biosciences Inc ENVB.O :
* ENVERIC BIOSCIENCES- EXPANDS IP PORTFOLIO WITH U.S. PATENT
FOR
NOVEL CARBOXYLATED PSILOCYBIN DERIVATIVES SUPPORTING EVM301
SERIES OF DRUG CANDIDATES
Source text for Eikon: ID:nBw51bksNa
Further company coverage: ENVB.O
((Reuters.Briefs@thomsonreuters.com))
Recent news on Enveric Biosciences
See all newsBrief: Enveric Biosciences Announces Positive Results From IND-Enabling ADMET Studies
Enveric Biosciences Q2 net loss widens
AtaiBeckley surges after report Lilly poised to buy psychedelic drug developer
Brief: Enveric Biosciences Initiates Investigational New Drug (IND)-Enabling Genotoxicity Studies Of Lead Neuroplastogen Candidate EB-003
Brief: Enveric Biosciences Reports Positive Preclinical Results From Phototoxicity Analysis For Lead Neuroplastogen Candidate Eb-003